|
|
|
Patients should try to come to consult us personally, for
those that cannot do that, please send or fax to the professional group your recent symptoms, examination, analysis, early diagnose and case history (including patient's address, telephone number, height, weight), after discussion and diagnosis by the professional group, the treatment plan will be informed to the patient and he/she should receive treatment by postage. One can consult the professional group anytime during the treatment.
Tel: +380937434009
+380636018551
Fax:+80971147553
Email:yizi_06@yahoo.com.cn |
|
Miss Wang +380937434009 |
Miss Wang +380636018551 |
Email:yizi_06@yahoo.com.cn |
Address:Bei Xi Liu Lu Zhan Dian Zi Bo Shan Dong China |
Remittance/Payment |
|
|
Gufang Chinese medicine complicated diseases research center is located at Shan Dong Province Zi Bo City, ZhangDian Bei Xi Liu Road; Zi Bo is situated between LuZhong mountain area and LuBei champagne, located at a unique location, its south joins with TaiShan, its north is near by Yellow River, its west is connected with Spring City JiNan, its east is near by beach cities-QingDao, YanTai and WeiHai; it is one of ShanDong Province's five main tourist spots and it is one of the eight tourism city.
>>>more |
|
Dr. Wang Yong, character Shurun, of Han Nationality, is born to the Chinese medicine aristocratic family, he has inherited the essence of traditional Chinese medicine, he uses ancient secret remedies as the base and he complies, matches the results with the special characteristics of modern chronic diseases, high possibility contracted diseases, complicated diseases associated with drugs resistance, …….
>>>more |
|
|
|
|
|
| FDA stresses birth defect risks with Roche drug |
|
| 2008-5-18 23:09:45 Viewed: [ Font:Large Medium Small] [ Close] |
|
|
Health regulators warned again Friday that Roche and Novartis drugs prescribed to organ transplant patients can cause miscarriages and birth defects when used by pregnant women.
The Food and Drug Administration last October said it received reports of miscarriages and infants born with ear and mouth birth defects after their mothers took Roche's CellCept. At the time, FDA added its most serious warning to CellCept and a similar Novartis AG drug, Myfortic.
FDA spokesman Christopher Kelly said the agency has not received any new reports of pregnancy-related problems, but was concerned some doctors may not have seen the initial warning.
CellCept and Myfortic are used to suppress the body's immune system to avoid organ rejection in transplant patients.
In a notice posted online Friday, FDA said that before prescribing the drugs doctors should confirm their transplant patients are not pregnant, and are using effective contraception.
FDA said most of the reported problems came from mothers who were taking CellCept before their pregnancies were detected. Some of the patients were taking the drug for conditions it was not approved to treat — including rheumatoid arthritis and lupus.
A spokesman for Roche said it has not received any new reports of miscarriages or birth defects since updating the drug's labeling. The company previously reported 25 miscarriages among 77 women exposed to the drug between 1995 and 2007.
The agency said it will continue working with Roche and Novartis to reduce use of the drugs by pregnant women.
Friday's FDA warning was the second in less than two months for Roche's CellCept, which was the Swiss drugmaker's sixth best-selling drug last year with revenue of nearly $2 billion.
Last month FDA said it was investigating 16 patients who developed a rare neurological disease while taking the drug.
The disease, known as progressive multifocal leukoencephalopathy, attacks the brain and central nervous system and is usually fatal. Symptoms include vision problems, loss of coordination and memory loss. Patients who survive are often permanently disabled, according to the FDA.
|
|
|
